RxDoctor Payments DataLook up a doctor →

Sean Halleran, MD

Clinical Cardiac Electrophysiology · Oklahoma City, OKNPI 1770773491

Payments from drug & device makers

$106,841in general payments, 2019–2025

Across 467 payments — averaging $228.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Atricure, Inc.$69K
  • Johnson & Johnson$12K
  • Abbott$8K
  • Pfizer$6K
  • Sanofi-aventis U.S. LLC$4K
  • E.r. Squibb & Sons, L.L.C.$3K
  • plus $6K from 18 others

What the payments were for

  • Consulting fees$63,38060%
  • Speaking & faculty fees$18,92518%
  • Travel & lodging$8,8848%
  • Food & beverage$14,10513%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$106,841 in reported general payments places this provider in the 70th percentile of 30 clinical cardiac electrophysiology providers in Oklahoma.

See all clinical cardiac electrophysiology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$473,005
Medicare patients
1,915
Services billed
7,338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban640$558,277
XareltoRivaroxaban250$238,222
MultaqDronedarone Hcl106$130,053
Dofetilide334$58,075
EntrestoSacubitril/Valsartan12$14,914
Flecainide Acetate239$10,798
SotalolSotalol Hcl160$3,370
Potassium Chloride54$2,965
Carvedilol142$2,792
Mexiletine Hcl30$2,453
Diltiazem 24hr Er (Cd)Diltiazem Hcl59$1,892
Metoprolol Tartrate171$1,669
Metoprolol Succinate109$1,391
Lisinopril80$944
Losartan Potassium45$697

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$5,643$558,277640 claims
Johnson & JohnsonXarelto$11,694$238,222250 claims
Sanofi-aventis U.S. LLCMultaq$3,504$130,053106 claims
NovartisEntresto$108$14,91412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 30 clinical cardiac electrophysiology providers in Oklahoma.

Other clinical cardiac electrophysiology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →